TG Therapeutics Inc (TGTX)

[stockguard]

Also on Tuesday:

TG Therapeutics analyst commentary at Jefferies TG Therapeutics 16% selloff yesterday 'excessive,' says Jefferies. Jefferies analyst Matthew Andrews calls the 16% pullback yesterday in shares of TG Therapeutics "excessive" and recommends buying the dip. The FDA feedback that use of overall response rate to support accelerated approval is a review issue "seems obvious and not a major negative," Andrews tells investors in a research note. The agency working with TG to identify how to use the Genuine study's progression free survival to support full approval is positive, suggesting it sees ublituximab's benefit in chronic lymphocytic leukemia, the analyst adds. Andrews keeps a Buy rating on TG Therapeutics with a $23 price target.